Publications

Molecular cell

Loss of nuclear DNA ligase III reverts PARP inhibitor resistance in BRCA1/53BP1 double-deficient cells by exposing ssDNA gaps.

18-11-2021

Key

Cancer discovery

Paradoxical activation of oncogenic signaling as a cancer treatment strategy.

27-03-2024

Cell reports. Medicine

Targeting of vulnerabilities of drug-tolerant persisters identified through functional genetics delays tumor relapse.

19-03-2024

The EMBO journal

PARG-deficient tumor cells have an increased dependence on EXO1/FEN1-mediated DNA repair.

01-03-2024

EMBO molecular medicine

Luminal breast cancer identity is determined by loss of glucocorticoid receptor activity.

07-12-2023

Molecular cell

Locus-specific proteome decoding reveals Fpt1 as a chromatin-associated negative regulator of RNA polymerase III assembly.

07-12-2023

Nucleic acids research

PAXIP1 and STAG2 converge to maintain 3D genome architecture and facilitate promoter/enhancer contacts to enable stress hormone-dependent transcription.

13-10-2023

Molecular oncology

Rational combination of SHP2 and mTOR inhibition for the treatment of hepatocellular carcinoma.

01-06-2023

Cell reports

Multi-omics analysis reveals distinct non-reversion mechanisms of PARPi resistance in BRCA1- versus BRCA2-deficient mammary tumors.

30-05-2023

Breast cancer research : BCR

Systematic screening identifies ABCG2 as critical factor underlying synergy of kinase inhibitors with transcriptional CDK inhibitors.

05-05-2023

Cancer immunology research

Inhibitor of Apoptosis Proteins Antagonist Induces T-cell Proliferation after Cross-Presentation by Dendritic Cells.

03-04-2023

Journal of experimental & clinical cancer research : CR

Subtype-specific kinase dependency regulates growth and metastasis of poor-prognosis mesenchymal colorectal cancer.

03-03-2023

Haematologica

Inhibition of casein kinase 2 sensitizes mantle cell lymphoma to venetoclax through MCL-1 downregulation.

01-03-2023

Cell reports. Medicine

Genetic screens reveal new targetable vulnerabilities in BAP1-deficient mesothelioma.

21-02-2023

Proceedings of the National Academy of Sciences of the United States of America

Mammalian life depends on two distinct pathways of DNA damage tolerance.

24-01-2023

EBioMedicine

Sustained activation of EGFR-ERK1/2 signaling limits the response to tigecycline-induced mitochondrial respiratory deficiency in liver cancer.

01-01-2023

Molecular cancer therapeutics

NOTCH Signaling Limits the Response of Low-Grade Serous Ovarian Cancers to MEK Inhibition.

02-12-2022

Bio-protocol

An Unbiased CRISPR-Cas9 Screening Method for the Identification of Positive and Negative Regulatory Proteins of Cell Adhesion.

05-11-2022

Nature cancer

cFLIP suppression and DR5 activation sensitize senescent cancer cells to senolysis.

01-11-2022

Nature communications

A doxycycline- and light-inducible Cre recombinase mouse model for optogenetic genome editing.

28-10-2022

PloS one

Indisulam synergizes with palbociclib to induce senescence through inhibition of CDK2 kinase activity.

07-09-2022

Life science alliance

Genetic and compound screens uncover factors modulating cancer cell response to indisulam.

01-09-2022

Nucleic acids research

Division of labor within the DNA damage tolerance system reveals non-epistatic and clinically actionable targets for precision cancer medicine.

22-07-2022

Nature communications

A loss-of-adhesion CRISPR-Cas9 screening platform to identify cell adhesion-regulatory proteins and signaling pathways.

19-04-2022

Cancers

Ribociclib Induces Broad Chemotherapy Resistance and EGFR Dependency in ESR1 Wildtype and Mutant Breast Cancer.

16-12-2021

Genome medicine

Targeting CDC7 potentiates ATR-CHK1 signaling inhibition through induction of DNA replication stress in liver cancer.

18-10-2021

Molecular cancer research : MCR

Identification of Autophagy-Related Genes as Targets for Senescence Induction Using a Customizable CRISPR-Based Suicide Switch Screen.

01-10-2021

Cell reports

The Cancer SENESCopedia: A delineation of cancer cell senescence.

27-07-2021

Nature communications

Glucocorticoid receptor triggers a reversible drug-tolerant dormancy state with acquired therapeutic vulnerabilities in lung cancer.

16-07-2021

Nature

EGFR activation limits the response of liver cancer to lenvatinib.

01-07-2021

Scientific reports

A kinome-centered CRISPR-Cas9 screen identifies activated BRAF to modulate enzalutamide resistance with potential therapeutic implications in BRAF-mutated prostate cancer.

01-07-2021

EBioMedicine

It takes two to tango, and the right music: Synergistic drug combinations with cell-cycle phase-dependent sensitivities.

01-07-2021

Molecular cell

Impact of chromatin context on Cas9-induced DNA double-strand break repair pathway balance.

20-05-2021

Genome medicine

Correction to: A role for the unfolded protein response stress sensor ERN1 in regulating the response to MEK inhibitors in KRAS mutant colon cancers.

10-02-2021

eLife

A powerful drug combination strategy targeting glutamine addiction for the treatment of human liver cancer.

05-10-2020

Life science alliance

The RECQL helicase prevents replication fork collapse during replication stress.

01-10-2020

Gut

CDK12 inhibition mediates DNA damage and is synergistic with sorafenib treatment in hepatocellular carcinoma.

01-04-2020

Nature cancer

Old drugs with new tricks.

01-02-2020

European journal of immunology

High-throughput compound screen reveals mTOR inhibitors as potential therapeutics to reduce (auto)antibody production by human plasma cells.

01-01-2020

eLife

TLE3 loss confers AR inhibitor resistance by facilitating GR-mediated human prostate cancer cell growth.

19-12-2019

Nature

Inducing and exploiting vulnerabilities for the treatment of liver cancer.

01-10-2019

Cancer research

Inhibition of Ataxia-Telangiectasia Mutated and RAD3-Related (ATR) Overcomes Oxaliplatin Resistance and Promotes Antitumor Immunity in Colorectal Cancer.

01-06-2019

The Journal of experimental medicine

Ezh2 inhibition in Kras-driven lung cancer amplifies inflammation and associated vulnerabilities.

03-12-2018

Genome medicine

A role for the unfolded protein response stress sensor ERN1 in regulating the response to MEK inhibitors in KRAS mutant colon cancers.

27-11-2018

Journal of hepatology

Phospho-ERK is a biomarker of response to a synthetic lethal drug combination of sorafenib and MEK inhibition in liver cancer.

01-11-2018

Oncogene

ARID1A mutation sensitizes most ovarian clear cell carcinomas to BET inhibitors.

01-08-2018

Cancer research

Integrative Modeling Identifies Key Determinants of Inhibitor Sensitivity in Breast Cancer Cell Lines.

01-08-2018

Cell reports

Neutrophils Kill Antibody-Opsonized Cancer Cells by Trogoptosis.

26-06-2018

Cell research

A CRISPR screen identifies CDK7 as a therapeutic target in hepatocellular carcinoma.

01-06-2018

Molecular cancer therapeutics

PIM Kinases Are a Potential Prognostic Biomarker and Therapeutic Target in Neuroblastoma.

01-04-2018